HUM - Educational Analysis * US Equities
Educational Analysis * US Equities

HUM

Earnings behavior, post-earnings drift, and the gap between consensus and the market's real expectation - the educational primer before you look at the institutional verdict.

Educational content only - not investment advice. Nothing on this page is a recommendation to buy or sell any security. Historical patterns do not predict future outcomes. Consult a licensed financial advisor before making any trading decision.
Published byGamma QC editorial
TickerHUM
CategoryEducational primer
Last reviewedNovember 9, 2026
You're viewing an older edition of this page.Read the latest edition →

Business profile & competitive position

Humana Inc. is a Louisville, Kentucky-based health company classified in the Healthcare sector, specifically the Medical - Healthcare Plans industry. The company operates through two reportable segments: Insurance and CenterWell. The Insurance segment covers Medicare, state-based Medicaid, individual and employer plans, specialty benefits, military services, and a pharmacy benefits manager (PBM). CenterWell includes pharmacy solutions, primary care, and home solutions. As of December 31, 2025, Humana served approximately 15.0 million members in medical benefit plans and an additional 4.7 million members in specialty products.

The financial footprint is what one would expect from a large, regulated health plan operator rather than a high-margin healthcare services business. The net margin is 0.8% and ROE is 6.7%. Those figures imply a business driven by scale, regulatory compliance, and cost discipline rather than by wide pricing power. A competitive position built on integrated care, vertical delivery assets, and government-backed premium streams appears durable, but the thin margin also shows how tightly reimbursed the business is. For context, 14% of 2025 individual Medicare Advantage revenue came from Florida alone, covering approximately one million members, so geographic concentration is another defining feature of the franchise.

Financial posture

Humana currently carries a market capitalization of $51.4 billion and trades at a price-to-earnings ratio of 41.2. Those multiples sit well above what the 0.8% net margin and 6.7% ROE would normally justify, creating a visible valuation-to-profitability gap. At the snapshot date, the stock price was $428.02, the 50-day exponential moving average was $406.46, and the RSI was 57.9, placing the shares in broadly neutral technical territory.

The 41.2 P/E suggests the market is pricing in either a meaningful earnings recovery, continued Medicare Advantage enrollment growth, or the defensive characteristics of a stock with a beta of 0.74. Low market sensitivity can attract a premium in uncertain environments, but the combination of thin current profitability and an elevated multiple also means there is little room for operational disappointment if 2027 results do not improve materially over the recent past.

Strategic priorities & outlook

Humana's most recent 10-K filing outlines a strategy centered on an integrated care delivery model that combines quality care, high member engagement, and sophisticated data analytics. Near-term operational priorities include improving the consumer experience by simplifying interactions, engaging members in clinical programs, and helping providers transition from fee-for-service to value-based arrangements.

CenterWell is the visible execution arm of that strategy. As of December 31, 2025, CenterWell Primary Care operated 350 clinics, employed approximately 1,300 primary care providers, and served roughly 491,100 patients. On the value-based care front, approximately 2,260,900 members, or 15.1% of total medical membership, were covered under shared risk value-based arrangements, including 37.1% of total individual Medicare Advantage membership.

Federal contracts remain the dominant revenue engine. In 2025, 83% of total premiums and services revenue came from contracts with the federal government. The strategic direction points toward deeper vertical integration—owning more of the pharmacy, primary care, and home-care cost stack—rather than relying solely on underwriting spread. Whether that integration lifts the 0.8% net margin materially depends on execution against those stated priorities.

Macro & geopolitical exposure

As a Medical - Healthcare Plans operator, Humana's macro exposure is primarily regulatory and political rather than cyclical. Medicare Advantage payment rates, state Medicaid expansion or contraction, and federal reimbursement policy directly affect both revenue and margin. CMS rate announcements, risk adjustment rules, and prescription drug pricing policy can move the bottom line faster than nominal GDP growth.

The business also carries meaningful geographic concentration exposure: 14% of 2025 individual Medicare Advantage revenue came from Florida. That concentration can amplify risks from regional cost trends, state Medicaid policy shifts, or location-specific public health developments. From a capital-markets perspective, the 0.74 beta indicates the stock has historically moved less than the broad market, consistent with the defensive, rate-regulated nature of government-backed healthcare revenue.

Recent developments

On November 9, 2026, Benzinga reported that analysts raised their forecasts following Humana's Q3 results, while BusinessWire reported that the company commenced offers to purchase for cash certain of its outstanding debt securities. Both releases followed the third-quarter earnings report dated November 6, 2026. On November 7, 2026, MarketBeat published a recap of what Humana said on its Q3 earnings call, and 247WallSt noted that Medicare had locked in most 2027 cost figures but that one big number was still missing—a likely reference to pending rate or reimbursement guidance.

Together, the headlines point to a period of improved analyst sentiment, active balance-sheet management, and investor focus on the next set of Medicare-related policy details that will shape 2027 pricing and margins.

Earnings behavior & post-earnings drift

Humana has delivered a perfect beat rate over the last eight reported quarters, exceeding estimates in all eight instances with an average earnings surprise of 8.9%. The average 5-day price move following those reports is 3.16% to the upside, suggesting the market has generally needed a few sessions to digest results rather than fully repricing on the first day.

The four most recent quarters illustrate that dynamic. For the quarter reported November 6, 2026, actual EPS was $-0.70 against an estimate of $-1.00, a 30% positive surprise, but the stock fell 1.18% the next day and was flat over the following five days. On July 29, 2026, actual EPS of $7.61 beat the $7.27 estimate by 4.7%, producing a 0.34% one-day gain and a slight -0.44% five-day drift. The April 29, 2026 quarter saw a narrow 0.7% beat with $10.31 versus $10.24, yet the stock dropped 2.75% the next day before recovering 1.32% over the next five sessions. The strongest post-report move came from the February 11, 2026 quarter, when a 1% positive surprise on EPS of $-3.96 versus $-4.00 produced a 1.96% one-day rally and an 8.61% five-day drift.

With the next scheduled report on February 10, 2027 before the open, the consensus EPS estimate stands at $-7.8354. The historical pattern of beats shows that Humana's management has consistently guided conservatively relative to the market's real expectation, but past performance does not guarantee the next report will follow the same path.

Frequently Asked Questions

Why is Humana's net margin so low at 0.8% despite steady earnings beats?

The 0.8% net margin reflects the cost structure of the managed-care industry, where premium revenue is large but medical claims and operating expenses absorb most of the top line. Beating estimates by an average of 8.9% over eight quarters shows management has guided conservatively, not that the underlying business is unusually profitable.

What does the 41.2 P/E mean when ROE is only 6.7%?

The gap between a 41.2 P/E and a 6.7% ROE suggests investors are paying a premium for anticipated earnings recovery, Medicare Advantage growth, or the defensive characteristics associated with Humana's 0.74 beta. It also means the valuation could compress quickly if 2027 results disappoint.

How much of Humana's business depends on the federal government?

According to the 10-K summary, 83% of 2025 total premiums and services revenue came from contracts with the federal government. That concentration makes Medicare and federal reimbursement policy central to both revenue stability and earnings risk.

For a deeper dive into Humana's full institutional verdict, including detailed consensus estimates, rating distributions, and forward-looking analyst commentary, readers should consult the complete institutional research coverage rather than relying solely on historical patterns.

Real Data - Gamma QC Earnings IntelligenceAs of Nov 9, 2026
Humana Inc. · Healthcare / Medical - Healthcare Plans
$51.4BMarket cap
41.2P/E
0.8%Net margin
6.7%ROE
100%Beat rate, last 8Q
8.9%Avg EPS surprise
3.16%Avg 5-day move after earnings
2027-02-10Next earnings
ReportedActualEstimateSurprise1D Move5D Move
2026-11-06$-0.7$-1+30%-1.18%null%
2026-07-29$7.61$7.27+4.7%+0.34%-0.44%
2026-04-29$10.31$10.24+0.7%-2.75%+1.32%
2026-02-11$-3.96$-4+1%+1.96%+8.61%
2025-11-05$3.24$2.93+10.6%--
2025-07-30$6.27$5.92+5.9%--

Previous HUM editions

Beyond the primer

Get the institutional verdict on HUM

Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.

Read the HUM verdict at Gamma QC
$49 Pro / $249 RIA * gammaqc.com

Verify authenticity

Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.